Actively Recruiting
Phase 1 Study of REGN5837 Combined With Odronextamab for Adults With Aggressive B-cell Non-Hodgkin Lymphomas
Led by Regeneron Pharmaceuticals · Updated on 2026-05-19
107
Participants Needed
20
Research Sites
47 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating an experimental drug called REGN5837 in combination with another drug, odronextamab, for adults with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas B-NHLs. The study aims to find a safe dose of REGN5837 when combined with odronextamab and then assess how well this combination works. Additional questions include side effects, drug levels in the blood, and whether the body develops antibodies that might affect the drugs action. The study has two parts. The first part involves dose escalation to determine a safe dose of REGN5837 combined with odronextamab. The second part uses the safe dose found to evaluate the treatments effectiveness. Both drugs are administered according to the study protocol. The study does not use randomization or masking. Participants will be monitored for side effects and adverse events for up to approximately five years. Researchers will measure drug concentrations in the blood, antibody responses, and cancer response using the Lugano Classification. Tumor biopsies may be required during the dose expansion phase. The study includes regular assessments and follows participants long term to evaluate treatment safety and outcomes.
CONDITIONS
Brief Title
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
